Crop Type Maps for Operational Global Agricultural Monitoring.

Crop type maps identify the spatial distribution of crop types and underpin a large range of agricultural monitoring applications ranging from early warning of crop shortfalls, crop condition assessments, production forecasts, and damage assessment from extreme weather, to agricultural statistics, agricultural insurance, and climate mitigation and adaptation decisions. Despite their importance, harmonized, up-to-date global crop type maps of the main food commodities do not exist to date. To address this critical data gap of global-scale consistent, up-to-date crop type maps, we harmonized 24 national and regional datasets from 21 sources covering 66 countries to develop a set of Best Available Crop Specific masks (BACS) over the major production and export countries for wheat, maize, rice, and soybeans, in the context of the G20 Global Agriculture Monitoring Program, GEOGLAM.

Patient Variables Associated with Nafcillin Plasma Concentrations and Toxicity.

PRIMARY OBJECTIVE: To retrospectively review nafcillin plasma concentrations (CNAF ) and determine nafcillin clearance (CLNAF ) in a diverse sample of patients treated with nafcillin administered as a continuous infusion. SECONDARY OBJECTIVE: To identify clinical variables associated with CLNAF and nafcillin-related adverse drug reactions (ADRs). METHODS: Retrospective chart review of patients receiving nafcillin via continuous infusion at University of Utah Health Care from 2006 to 2013 who had at least one steady-state CNAF measured. CLNAF was determined by dividing the nafcillin rate of infusion by CNAF . Adverse drug reactions (ADRs) were defined using the National Institutes of Health, Division of Microbiology and Infectious Diseases criteria and scored for probability of association with nafcillin by using Naranjo criteria. Multivariate models were constructed to identify independent variables associated with CLNAF and ADRs. MAIN RESULTS: Seventy-six CNAF from 54 patients were included. Median CLNAF was 13.9 L/hour (range ≤ 4.2 to 36.9 L/hr). Congestive heart failure (p=0.007), hyperbilirubinemia (p<0.0001), and serum creatinine (p<0.0001) were associated with reduced CLNAF , and Hispanic race (p=0.002) was associated with increased CLNAF by multivariate analysis. Twenty patients (37.0%) experienced an ADR. CNAF were significantly higher between patients that experienced an ADR and those that did not (66.0 vs 25.5 mg/L, p<0.001). Individual ADRs associated with CNAF included hepatotoxicity (62.8 vs 27.0 mg/L, p=0.001), nausea/vomiting (80.0 vs 28.5 mg/L, p=0.01), and diarrhea (66.5 vs 26.5 mg/L, p<0.001). Multivariate analysis identified CNAF as being independently associated with ADRs. A putative toxicity relationship between CNAF and predicted probability of ADR was established. CONCLUSIONS: Several patient variables were associated with impaired CLNAF , and elevated CNAF were associated with ADRs. Additional studies assessing the utility of nafcillin therapeutic drug monitoring to minimize toxicity are warranted.

Future habitat loss and extinctions driven by land-use change in biodiversity hotspots under four scenarios of climate-change mitigation.

Numerous species have been pushed into extinction as an increasing portion of Earth's land surface has been appropriated for human enterprise. In the future, global biodiversity will be affected by both climate change and land-use change, the latter of which is currently the primary driver of species extinctions. How societies address climate change will critically affect biodiversity because climate-change mitigation policies will reduce direct climate-change impacts; however, these policies will influence land-use decisions, which could have negative impacts on habitat for a substantial number of species. We assessed the potential impact future climate policy could have on the loss of habitable area in biodiversity hotspots due to associated land-use changes. We estimated past extinctions from historical land-use changes (1500-2005) based on the global gridded land-use data used for the Intergovernmental Panel on Climate Change Fifth Assessment Report and habitat extent and species data for each hotspot. We then estimated potential extinctions due to future land-use changes under alternative climate-change scenarios (2005-2100). Future land-use changes are projected to reduce natural vegetative cover by 26-58% in the hotspots. As a consequence, the number of additional species extinctions, relative to those already incurred between 1500 and 2005, due to land-use change by 2100 across all hotspots ranged from about 220 to 21000 (0.2% to 16%), depending on the climate-change mitigation scenario and biological factors such as the slope of the species-area relationship and the contribution of wood harvest to extinctions. These estimates of potential future extinctions were driven by land-use change only and likely would have been higher if the direct effects of climate change had been considered. Future extinctions could potentially be reduced by incorporating habitat preservation into scenario development to reduce projected future land-use changes in hotspots or by lessening the impact of future land-use activities on biodiversity within hotspots.

La Futura Pérdida de Hábitat y Extinciones Causados por el Cambio en el Uso de Suelo en los Puntos Clave de Biodiversidad bajo Cuatro Escenarios de Mitigación de Cambio Climático Resumen Se ha llevado a numerosas especies a la extinción conforme una porción creciente de la superficie terrestre ha sido adueñada por actividades humanas. En el futuro, la biodiversidad global se verá afectada tanto por el cambio climático como por el cambio en el uso de suelo, de los cuales el último es actualmente el principal conductor de la extinción de especies. La manera en que las sociedades aborden el cambio climático afectará críticamente a la biodiversidad ya que las políticas de mitigación de cambio climático reducirán directamente los impactos del cambio climático; sin embargo, estas políticas influenciarán las decisiones de uso de suelo, lo que podría tener impactos negativos sobre el hábitat de numerosas especies. Evaluamos el impacto potencial que podrían tener las futuras políticas de clima sobre la pérdida del área habitable en los puntos clave de biodiversidad debido al cambio asociado en el uso de suelo. Estimamos las extinciones pasadas a partir de cambios históricos en el uso de suelo (1500 - 2005) con base en la extensión del hábitat, los datos de especies para cada punto clave, y la cuadrícula global de datos sobre uso de suelo, la cual fue utilizada para el Reporte de la Quinta Evaluación del Panel Intergubernamental sobre Cambio Climático. Después estimamos las extinciones potenciales causadas por futuros cambios en el uso de suelo bajo escenarios alternativos de cambio climático (2005 - 2100). El número de extinciones de especies adicionales, en relación con aquellas ya provocadas entre 1500 y 2005, causadas por el cambio en el uso de suelo para 2100 en todos los puntos clave, varió aproximadamente de 220 a 21, 000 (0.2% a 16%), dependiendo del escenario de mitigación de cambio climático y factores biológicos, como la pendiente de la relación especies-área y la contribución de la tala a las extinciones. Estas estimaciones de las extinciones potenciales en el futuro fueron causadas solamente por el cambio en el uso de suelo y probablemente habrían sido más altas si se hubiesen considerado los efectos directos del cambio climático. Las extinciones futuras podrían reducirse potencialmente al incorporar la preservación del hábitat al desarrollo del escenario para reducir los futuros cambios en el uso de suelo en los puntos clave o al disminuir el impacto de las futuras actividades de uso de suelo sobre la biodiversidad dentro de los puntos clave.

A multicompartment mathematical model of cancer stem cell-driven tumor growth dynamics.

Tumors are appreciated to be an intrinsically heterogeneous population of cells with varying proliferation capacities and tumorigenic potentials. As a central tenet of the so-called cancer stem cell hypothesis, most cancer cells have only a limited lifespan, and thus cannot initiate or reinitiate tumors. Longevity and clonogenicity are properties unique to the subpopulation of cancer stem cells. To understand the implications of the population structure suggested by this hypothesis--a hierarchy consisting of cancer stem cells and progeny non-stem cancer cells which experience a reduction in their remaining proliferation capacity per division--we set out to develop a mathematical model for the development of the aggregate population. We show that overall tumor progression rate during the exponential growth phase is identical to the growth rate of the cancer stem cell compartment. Tumors with identical stem cell proportions, however, can have different growth rates, dependent on the proliferation kinetics of all participating cell populations. Analysis of the model revealed that the proliferation potential of non-stem cancer cells is likely to be small to reproduce biologic observations. Furthermore, a single compartment of non-stem cancer cell population may adequately represent population growth dynamics only when the compartment proliferation rate is scaled with the generational hierarchy depth.

Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients.

PURPOSE: The visual compatibility of i.v. medications routinely used in bone marrow transplant recipients was studied. METHODS: A total of 17 drug combinations were tested using simulated Y-site administration. Medications were prepared to the standard concentrations used at University of Utah Health Care and infused at the appropriate rate. For each combination, the two drugs had 99 cm of shared tubing. At the end of the shared tubing was a 0.8-microm filter disk. All of the drug combinations were tested in triplicate. After the infusion was complete, each filter was bubble-point tested to ensure filter integrity and to remove residual solution. The tubing and dried filter were examined by eye as well as a magnification microscope. Drug combinations were considered incompatible if a precipitate or color change was visible to the naked eye during filtration or if the number of particles observed under the microscope exceeded 12 particles of > or =10 microm in diameter per milliliter of solution or if 2 or more particles of > or =25 microm in diameter per milliliter of solution were observed, per guidelines established by the United States Pharmacopeia for large-volume injections. RESULTS: Of the 17 drug combinations tested, 5 combinations were observed to be visually incompatible. All of the incompatible combinations included acyclovir as the primary infusion. Acyclovir was incompatible with cyclosporine, diphenhydramine, gentamicin, granisetron, and metoclopramide. CONCLUSION: Of the 17 drug combinations tested, 5 combinations were observed to be visually incompatible during simulated Y-site injection. The combinations found to be visually incompatible included acyclovir with cyclosporine, diphenhydramine, gentamicin, granisetron, or metoclopramide.

Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery.

PURPOSE: The physical compatibility of i.v. caspofungin with other commonly used i.v. medications was tested. METHODS: Two methods were used to combine caspofungin and the secondary drugs. For drugs administered by i.v. push, caspofungin was delivered through a poly-vinyl chloride (PVC) i.v. solution set with secondary drugs injected into the Y-site of the i.v. extension set. For drugs given by i.v. infusion (over 10 minutes), secondary drugs were infused into the Y-site of the i.v. solution set through microbore PVC tubing. The two drugs shared 39 in of tubing. Attached to each end of the i.v. extension set were 0.8-mum filter disks. All drug combinations were tested three times; after each infusion, the filters were bubble-point tested. Drug combinations were considered physically compatible if no visible precipitate was seen and no color change was noted by the unaided eye during the infusion, or if the number of particles found on the filter under a microscope did not exceed the number stated in United States Pharmacopeia guidelines for particulate levels of large-volume parenteral fluids. RESULTS: A total of 8 of the 31 drugs tested (acyclovir, ceftriaxone, cefazolin, clindamycin, furosemide, heparin, pantoprazole, and piperacillin-tazobactam) were found to be physically incompatible with caspofungin. CONCLUSION: Caspofungin acetate was physically compatible during Y-site injection with 23 of 31 medications tested.

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.

Serious gram-positive infections present an increasingly common therapeutic dilemma. Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials. We describe a patient with disseminated community-acquired methicillin-resistant Staphylococcus aureus infection who experienced a possible drug interaction between linezolid and rifampin that resulted in decreased serum linezolid levels. To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin. Although we hypothesize that the reaction was caused by P-glycoprotein expression, further study is warranted.